Loading...
Market
How many adverse events will be reported for Lymphir by December 31, 2024?
2
Resolution / Starting Odds
Less than 50 • 25%
50 to 100 • 25%
100 to 200 • 25%
More than 200 • 25%
FDA adverse event reporting database
Story
Citius Pharmaceuticals Gains FDA Approval for Lymphir with Boxed Warning
Aug 8, 2024, 01:30 PM
Citius Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its blood cancer therapy, Lymphir (denileukin diftitox-cxdl), aimed at treating adults with relapsed or refractory cutaneous T-cell lymphoma. This approval marks a significant milestone for Citius as it secures its first FDA approval. Lymphir is designed for patients who have undergone at least one prior treatment. The FDA's decision includes a boxed warning, highlighting potential risks associated with the therapy. The approval is expected to provide a new therapeutic option for patients with limited treatment choices.
View original story
Similar markets
AE rate < 20% • 25%
AE rate 20-30% • 25%
AE rate 30-40% • 25%
AE rate > 40% • 25%
Yes • 50%
No • 50%
None reported • 25%
Few minor events • 25%
Significant events • 25%
Major public health concern • 25%
None • 25%
Mild • 25%
Moderate • 25%
Severe • 25%
Attributed to vaccine • 25%
Attributed to unrelated causes • 25%
Inconclusive • 25%
No further information released • 25%
Less than 300 • 25%
300 to 399 • 25%
400 to 499 • 25%
500 or more • 25%
Less than 80,000 • 25%
80,000 to 90,000 • 25%
90,000 to 100,000 • 25%
More than 100,000 • 25%
Yes • 50%
No • 50%
No reports • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
Less than 500 cases • 25%
500-1000 cases • 25%
1001-1500 cases • 25%
More than 1500 cases • 25%
0-10 • 25%
11-20 • 25%
21-30 • 25%
More than 30 • 25%
Less than 40,000 • 25%
40,000 to 50,000 • 25%
50,000 to 60,000 • 25%
More than 60,000 • 25%